Company Analysis
Sign in

Celldex Therapeutics, Inc. (CLDX)

Nasdaq: CLDX · In Vitro & In Vivo Diagnostic Substances · Hampton, NJ · filing with the SEC since 1995
Full chart Alerts Compare
Grade5.1
◀ Past 3.8● Present 6.0▶ Future 5.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

89 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Celldex Therapeutics, Inc.’s names, not what it holds today.

Patents granted
89
89 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 5 in 2024 and 1 in 2023
Applications published
69
4 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Celldex Therapeutics, Inc. its own name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in GB)
43 granted
35 published
Celldex Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
33 published
T Cell Sciences, Inc. a former name
US, as the owner printed on each patent
24 granted
0 published
AVANT Immunotherapeutics, Inc. a former name
US, as the owner printed on each patent
22 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 13, 202512,297,266Agonistic antibodies that bind human CD40 and uses thereofPharmaceuticalsCelldex Therapeutics, Inc.
May 21, 202411,987,626Treatment of eosinophil or mast cell related disordersPharmaceuticalsCelldex Therapeutics, Inc.
Apr 23, 202411,965,031Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatmentPharmaceuticalsCelldex Therapeutics, Inc.
Feb 6, 202411,891,452Anti-kit antibodies and uses thereofPharmaceuticalsCelldex Therapeutics, Inc.
Jan 30, 202411,884,734Anti-MET antibodies and methods of use thereofPharmaceuticalsCelldex Therapeutics, Inc.
Jan 30, 202411,884,699Anti-KIT antibodies and uses thereofPharmaceuticalsCelldex Therapeutics, Inc.
Jan 3, 202311,541,076Chimeric antigen receptors targeting TIM-1BiotechnologyCelldex Therapeutics, Inc.
Oct 4, 202211,459,393Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsPharmaceuticalsCelldex Therapeutics, Inc.
May 17, 202211,332,537Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsPharmaceuticalsCelldex Therapeutics, Inc.
Nov 23, 202111,180,566Antibodies that bind human CD27 and uses thereofPharmaceuticalsCelldex Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0346671ANTI-PD-L1 ANTIBODIES AND METHODS OF USE THEREOFPharmaceuticalsCelldex Therapeutics, Inc.
May 15, 20252025/0154274USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENTPharmaceuticalsCelldex Therapeutics, Inc.
Apr 10, 20252025/0115663AGONISTIC ANTIBODIES THAT BIND CD40PharmaceuticalsCelldex Therapeutics, Inc.
Feb 20, 20252025/0059291CD27 AGONISTSPharmaceuticalsCelldex Therapeutics, Inc.
Dec 19, 20242024/0417459ANTIBODIES AGAINST ILT4, BISPECIFIC ANTI-ILT4/PD-L1 ANTIBODY AND USES THEREOFBiotechnologyCelldex Therapeutics, Inc.
Dec 12, 20242024/0409639ANTI-ILT4 AND ANTI-PD-1 BISPECIFIC CONSTRUCTSBiotechnologyCelldex Therapeutics, Inc.
Oct 31, 20242024/0360235USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENTPharmaceuticalsCelldex Therapeutics, Inc.
Aug 29, 20242024/0287180TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERSPharmaceuticalsCelldex Therapeutics, Inc.
May 9, 20242024/0150493ANTI-KIT ANTIBODIES AND USES THEREOFPharmaceuticalsCelldex Therapeutics, Inc.
May 2, 20242024/0141063ANTI-KIT ANTIBODIES AND USES THEREOFPharmaceuticalsCelldex Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Biotechnology 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CLDX · research, not advice